The Takeaway few patients are being prescribed these life-saving drugs for diabetes management and reduced cardiovascular risk , possibly due to uncertainties of dosing, lack of knowledge of the CVOTs, clinical inertia, high costs, and tolerability
The tablet is not approved for weight management in children ages 12 or older or for treating metabolic dysfunction-associated steatohepatitis (MASH) , unlike the injection
Additional sections address prevalence, mortality and morbidity, caregiving, the dementia care workforce, and the use and costs of health care and services
References Xie X, Yang S, Deng S, Liu Y, Xu Z, He B
[DOI] [PubMed] [Google Scholar] [42].Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK
Confirmatory secondary endpoints, including 6-minute walk distance and C-reactive protein levels, further supported semaglutides efficacy.(12,13) While not powered for mortality or HF hospitalization, exploratory analyses suggest benefits beyond weight loss alone.(4,12) An echocardiography substudy further explored semaglutides potential disease-modifying mechanisms in HFpEF pathophysiology in detail.(4) A comparison of key clinical trials with agents demonstrating benefit in HFpEF can be found in Table 1
